Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MiHA mRNA-electroporated donor dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Radboud University Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
The **MiHA mRNA-electroporated donor dendritic cell vaccine** is an experimental, ex vivo-generated cellular immunotherapy developed by the Radboud University Nijmegen Medical Centre (Radboud UMC). It consists of donor-derived dendritic cells (DCs) that are electroporated with mRNA encoding hematopoietic-restricted minor histocompatibility antigens (MiHAs), such as HA-1 or LRH-1. Administered intravenously to patients following HLA-matched allogeneic stem cell transplantation (allo-SCT) for hematologic malignancies, the vaccine is designed to selectively boost graft-versus-tumor (GVT) immunity. By presenting these hematopoietic-restricted MiHAs, the vaccine stimulates and expands donor-derived CD8+ cytotoxic T cells to target and eliminate residual leukemia or lymphoma cells without triggering graft-versus-host disease (GvHD).
- Other names
- MiHA-loaded donor dendritic cell vaccineMiHA mRNA transfected dendritic cell productMiHA-loaded donor dendritic cell vaccinationMiHA-loaded donor DC vaccine
02
Targets
Minor histocompatibility antigen peptide-human leukocyte antigen complexesCD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on MiHA mRNA-electroporated donor dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MiHA mRNA-electroporated donor dendritic cell vaccine.